Stock Market Wire News Logo
Stock Market Wire News Logo
    • Login
    • Sign Up

Ad

Trending Stock Alerts

KURA Stock - Kura Oncology Stock Trading


home / stock / kura

KURA KURA Quote KURA Short KURA News KURA Articles KURA Message Board

MWN AI Summary *

Kura Oncology Inc. (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the development of targeted therapies for cancer. Founded in 2007 and headquartered in San Diego, California, the company aims to address unmet medical needs in oncology through innovative drug candidates and robust clinical programs.

Kura's lead product candidate, Zymeworks, is an investigational drug designed for the treatment of various cancers, particularly those characterized by genetic mutations. The company is also developing a portfolio of other targeted therapies, including KURA-001, which showcases its commitment to advancing personalized medicine in oncology.

As of 2023, Kura is actively conducting clinical trials to evaluate the efficacy and safety of its drug candidates across different cancer types. Recent updates from their trials have indicated promising results, leading to increased investor interest and potential for future partnerships.

Financially, Kura Oncology is backed by institutional investors, allowing it to maintain a strong capital position for ongoing research and development activities. The company is strategically focusing on expanding its clinical pipeline and leveraging collaborations with larger pharmaceutical entities to expedite the development of its therapies.

In recent months, Kura's stock has been volatile, as is typical in the biotech sector, reacting to trial results, FDA decisions, and broader market trends. Analysts view Kura Oncology as an emerging player in the oncology space with potential for long-term growth, particularly if it successfully gains regulatory approval for its leading therapies.

Investors continue to monitor Kura’s progress as it navigates clinical trials and prepares for potential commercialization of its drug candidates. With a strong pipeline and focused development strategy, Kura Oncology remains a noteworthy company in the evolving landscape of cancer treatment.

MWN AI Analysis *

Kura Oncology Inc. (NASDAQ: KURA) operates in the biotech sector, focusing on the development of targeted therapies for cancer. As of October 2023, Kura's pipeline comprises promising candidates that address significant unmet needs in oncology, particularly in hematologic malignancies. Given the competitive landscape of cancer therapeutics, a comprehensive market analysis suggests several key considerations for investors.

Firstly, Kura's lead product candidate, tipifarnib, is making strides in clinical trials, particularly for patients with HRAS mutant tumors. Positive outcomes from ongoing studies would not only validate its therapeutic potential but could also position Kura as a leader in a niche market. The FDA's receptiveness to innovative solutions for rare cancers enhances the potential for accelerated approval pathways, which could be a substantial driver for the stock.

However, investors should remain aware of inherent risks, particularly around clinical trial outcomes and regulatory decisions. The biotech sector is notorious for volatility related to interim study results and FDA approvals. As Kura moves through its trial phases, transparent communication from management regarding progress will be crucial in maintaining investor confidence.

Furthermore, the general market conditions surrounding biotech and healthcare investments should be taken into account. Macroeconomic factors, such as interest rates and investor sentiment towards growth stocks, can profoundly impact share performance. Diversification and a cautious entry approach may be prudent for investors looking to capitalize on Kura’s potential upside while mitigating risk.

In conclusion, Kura Oncology represents a compelling opportunity in the oncology segment, bolstered by innovative therapies and a strong pipeline. However, careful monitoring of clinical developments and market trends will be essential for navigating the inherent volatility in biotech investments.

* MWN AI Summary and Analysis is based on asking OpenAI to summarize and analyze the company and stock symbol.


About | Kura Oncology Inc. (NASDAQ:KURA)

Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signalling pathways to drive the progression of various cancers. The company has a lead product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma. Geographically operation of the group is carried through the United States.

Quote | Kura Oncology Inc. (NASDAQ:KURA)

Last:$6.60
Change Percent: -0.16%
Open:$6.39
Close:$6.60
High:$6.695
Low:$6.3033
Volume:1,538,252
Last Trade Date Time:07/17/2025 03:40:42 pm

News | Kura Oncology Inc. (NASDAQ:KURA)

  • Kura Oncology: Ziftomenib Shift Towards Newly Diagnosed Mutant AML Patients Bodes Well

    2025-07-02 00:09:13 ET Kura Oncology ( KURA ) is in good shape with respect to its pipeline in terms of the development of its lead drug, ziftomenib, for the treatment of patients with relapsed/refractory NPM1-mutated Acute myeloid leukemia [AML]. Thanks to positive data from th...

    • July 02, 2025 12:09:13 am

    • |
    • SeekingAlpha
    • |
      • KURA Stock
      • KURA Quote
      • KURA Short
      • KURA News
      • KURA Articles
      • KURA Message Board
  • Kura Oncology rises after new early-stage trial data for leukemia therapy

    2025-06-12 08:38:15 ET More on Kura Oncology, Kyowa Kirin Co., Ltd. Kura Oncology, Inc. (KURA) Q1 2025 Earnings Call Transcript Prices of new U.S. drugs doubled over the past four years: report Kura Oncology targets 2028 MRD-negative CR results for frontline AML tria...

    • June 12, 2025 08:38:15 am

    • |
    • SeekingAlpha
    • |
      • KURA Stock
      • KURA Quote
      • KURA Short
      • KURA News
      • KURA Articles
      • KURA Message Board

Message Board Posts | Kura Oncology Inc. (NASDAQ:KURA)

Subject By Source When
* * $KURA Video Chart 04-28-2020 * * ClayTrader investorshub 04/28/2020 9:04:32 PM
Anybody out there? ! seppi08162 investorshub 12/19/2019 5:52:35 PM
KURA buy 19.00 stocktrademan investorshub 02/11/2018 5:50:43 PM
Feels risky here...feels like they're purposely notching it Lone Wolf investorshub 09/08/2017 3:17:02 PM
Looks like the markets are really starting to Lone Wolf investorshub 09/08/2017 2:26:26 PM

MWN AI FAQ **

What recent clinical trial results for Kura Oncology Inc. KURA have influenced its stock performance and investor sentiment?

Recent clinical trial results from Kura Oncology Inc. (KURA) showing promising efficacy in their drug programs for solid tumors have positively influenced stock performance and bolstered investor sentiment, reflecting growing confidence in their therapeutic potential.

How does Kura Oncology Inc. KURA's pipeline compare to its peers in oncology regarding potential market impact and innovation?

Kura Oncology Inc. (KURA) distinguishes itself in the oncology landscape with its innovative pipeline targeting unmet needs in precision medicine, notably with its lead candidates demonstrating strong potential for significant market impact compared to its peers.

What are the key financial metrics to consider when evaluating Kura Oncology Inc. KURA as a long-term investment opportunity?

Key financial metrics to consider when evaluating Kura Oncology Inc. (KURA) as a long-term investment include revenue growth, net income margin, cash burn rate, research and development expenses, market capitalization, and the clinical trial progress of its drug candidates.

How are partnerships and collaborations shaping the future prospects of Kura Oncology Inc. KURA within the biotech sector?

Partnerships and collaborations are enhancing Kura Oncology Inc.'s prospects in the biotech sector by providing access to additional resources, expertise, and market opportunities, thus accelerating the development of innovative therapies and improving competitive positioning.

** MWN AI Questions are based on asking OpenAI to ask and answer four questions about the company and stock symbol.

Stock Information

Get KURA Alerts

News, Short Squeeze, Breakout and More Instantly...

Kura Oncology Inc. Company Name:

KURA Stock Symbol:

NASDAQ Market:

-0.16% G/L:

$6.60 Last:

1,538,252 Volume:

$6.39 Open:

$6.60 Close:

Kura Oncology Inc. Website:

Kura Oncology Inc. Logo

Ad

Trending Stock Alerts
RECENT KURA NEWS
  • KURA - Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress

    – Encouraging clinical activity with deep responses demonstrated in the KOMET-007 trial with the combination of 600 mg ziftomenib with 7+3 in newly diagnosed patients with NPM1 -m and KMT2A -r AML – – 93% (41/44) and 89% (24/27) CRc observed in NPM1 -m an...

  • KURA - Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting

    – CR/CRh rate of 23% in pivotal Ph 2 cohort of R/R NPM1 -m AML patients – – Consistent efficacy with comparable CR/CRh rates and clinically meaningful MRD-negative responses across pre-specified subgroups, regardless of prior HSCT, prior venetoclax, or FLT3/IDH co...

  • KURA - Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML

    – New Drug Application based on positive results from the Phase 2 KOMET-001 trial – – FDA assigns a Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2025 – – Potential first approval of a menin inhibitor for the treatment of adul...

  • Research
  • Stock Search
  • News Releases
  • Articles
  • Topics
  • Message Boards
  • Trending Stocks
  • Trending Feed
  • Trending Alerts
  • Watchlist
  • Short Information
  • Stock Wall
  • Link Twitter
  • Sign Up
  • Login
  • Contact

Link your X Account

Link your X Account to Market Wire News

When you linking your X Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your X account.

Be alerted of any news about your stocks and see what other stocks are trending.



Connect with Us

Join our Telegram Alerts Channel

Telegram

Join our Discord

Discord

Get KURA Alerts

Get KURA Alerts

News, Short Squeeze, Breakout and More Instantly...

Sign up or login to continue

Sign up or login to continue.


Forgot password?




Mobile Number Subscribers

Market Wire News provides notifications to customers about updates, service, reminders, or products. Current and new customers of Market Wire News will enter their mobile numbers on a web opt-in form https://marketwirenews.com. Supported Carriers are as follows Alltel, AT&T, Cincinnati Bell, Dobson Cellular Systems, Inter Op, MetroPCS®, Nextel Communications, Sprint PCS, T-Mobile®, U.S. Cellular®, Verizon Wireless, and Virgin Mobile U.S. T-Mobile® is not liable for delayed or undelivered messages. There are no premium charges for joining Market Wire News service. Message and data rates may apply. Subscribers to Market Wire News service may receive up to 500 per month.

How to Opt Out

To opt-out of the Market Wire News program, send or text STOP, END, QUIT, CANCEL or UNSUBSCRIBE to (844) 931-3999. An unsubscribe message will be sent to your number confirming the cancellation, but no more messages will be sent after that one.

Mobile Support

For support or information about a Market Wire News, send or text HELP to (844) 931-3999. Optionally, you may email support@marketwirenews.com.


Disclaimer

This electronic content is for the purposes of solicitation subscriptions for Market Wire News. Market Wire News expects to generate new advertisement revenue resulting from the distribution of this electronic content. The amount of which is unknown at this time. Market Wire News is not a registered investment adviser or broker-dealer. This electronic content does not provide a professional analysis of a any stock financial position. any stock's financial position and all other information regarding the featured Company should be verified directly with any stock. This electronic content is provided as an information service only, and any statements and opinions in this electronic content should not be construed as an offer or solicitation to buy or sell any security. Market Wire News accepts no liability for any loss arising from an investor's reliance on or use of this electronic content. An investment in any company is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. Market Wire News does not own, buy, sell or plans to own, buy, sell, and of any stock's shares. This electronic content contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Please read our full disclaimer for compensation and more detailed information.

Advertise

Brand your company, advertise your products or services with our ad programs.

Advertise

Research

Stock Search

News Releases

Articles

Message Boards

Trending Stocks

Short Information

Stock Wall

Members

Log In

Sign Up

Stay Connected

| X

| Facebook

| BlueSky

| LinkedIn

| Telegram

| Discord


Contact

Privacy

Terms of Service

Disclaimer

© 2025 Market Wire News 1